Philippe Dro

Luciole Medical AG operates as a Swiss medical technology company developing brain oxygenation monitoring systems. The firm's products include Rheopatch, RheoSens, RheoLity and RheoControl. The company was founded in September 2017 and is headquartered in Zurich, Switzerland.

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.

Aleva Neurotherapeutics SA develops next-generation implants for deep brain stimulation therapy. Its micro fabricated devices enable target specific stimulation and optimization of current therapies. The company was founded by Claudio Pollo, Jean-Pierre Rosat, Philipe Renaud, Paul Pyzowski and André Mercanzini and in August 2008 and is headquartered in Lausanne, Switzerland.

GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020.

LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023.

Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands.

Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland.

Part of Grünenthal Pharma GmbH & Co. KG, Mestex AG is a Swiss pharmaceutical manufacturing company. The company is based in Basel, Switzerland. The CEO of the company is Olivier Valdenaire. Mestex was acquired by Grünenthal GmbH on April 12, 2021.